Document is current

Article History

Received: 26 January 2024

Accepted: 9 June 2024

First Online: 23 August 2024

Declarations

:

: Manuel Ruiz Borrego, Felipe Reyes-Cosmelli, Joanne Chiu, Mario Airoldi, Nicholas Turner, and Luis Fein have nothing to disclose. Yen-Shen Lu reports clinical trial study fees, grants for clinical study of <i>ESR1</i> mutation detected by cell-free DNA, advisory board consultation fees, and speaker fees from Novartis; consultation fees from Pfizer; contracted research and speaker fees from Roche, Pfizer, and MSD; speaker fees from Eisai, AstraZeneca, Eli Lilly, and Daiichi Sankyo; and serving on a clinical trial for AstraZeneca and advisory board for Daiichi Sankyo. Yeon Hee Park reports contracted research for AstraZeneca, Roche, Pfizer, Gencurix, and MSD; serving on an advisory board for AstraZeneca, Daiichi Sankyo, Pfizer, Roche, MSD, Eisai, Novartis, and Eli Lilly; and manuscript writing for Pfizer, Roche, MSD, and Novartis. Toshinari Yamashita reports honoraria for lectures from Chugai, Eli Lilly, Daiichi Sankyo, Eisai, Novartis, Taiho, AstraZeneca, Nippon Kayaku, Pfizer Japan, and Kyowa Kirin. Farhat Ghaznawi, Jyotika Singh, Kristyn Pantoja, Christian Schnell, and Murat Akdere report employment by and stock ownership in Novartis. Stephen Chia reports payment to their institution for conduct of a clinical trial with alpelisib and payment for advisory boards and CME talks from Novartis.

: All participants in each trial provided written informed consent. All trials were approved by an independent ethics committee and institutional review board at each site and were conducted per the Declaration of Helsinki and Good Clinical Practice.

: All participants in each trial provided written informed consent. All trials were approved by an independent ethics committee and institutional review board at each site and were conducted per the Declaration of Helsinki and Good Clinical Practice.

: Informed consent was obtained from all individual participants included in the SOLAR-1 and BYLieve trial.

: The animal research performed in this study complies with all ethical regulations. Experiments were conducted under license number BS-2741 approved by the Cantonal Veterinary Office of Basel Stadt. Novartis is an Association for Assessment and Accreditation of Laboratory Animal Care–accredited facility.